15 funding opportunities are listed in this category
Cure Congenital Muscular Dystrophy Research Grants
Cure CMD Research Grant GoalsCure CMD research goals reflect our mission to bring research, treatments and in the future, a cure for the congenital muscular dystrophies. 1. Identify new therapeutic targets in the CMDs 2. Identify small molecule compounds that work at these therapeutic target sites with priority towards drugs with existing pediatric FDA approval 3. Facilitate the drug development process to ensure that each positive drug identification with promising preliminary data can be brought rapidly to preclinical trials and subsequent treatment trials 4. Support and endorse clinical research, infrastructure and biomarker discovery required to launch effective and efficient clinical trials in rare disease 5. Advance drug discovery with a diverse treatment pipeline 6. Support new scientific investigators with innovative ideas and a commitment to CMD researchStruggle Against Muscular Dystrophy (S.A.M) CMD Translational Research Grant: Annual Deadline, Sept 15th.
S.A.M is a unique CMD advocacy group launched by two parents whose son has CMD. SAM’s focus is to support and foster CMD research through successful fundraising initiatives. The SAM Translational Research Award delivers upon its promise to target research focused on CMD treatment. The grant is made possible through Cure CMD and SAM collaboration and the Cure CMD research grant funding mechanism.Cure CMD and SAM invite proposals to award a 1-2 year grant focusing on pre-clinical and clinical investigations that will advance treatment for congenital muscular dystrophy (CMD). The total award is limited to $100,000 (direct costs only). Annual RFA deadline Sept 15th. Grant application above. On the First Page of the Cure CMD grant application, please specify S.A.M. CMD Translational Research Grant
Cure CMD General Research Grants: Annual Deadline Sept 15th.
Elisabeth Giauque Short Term CMD Research Grant: Cure CMD provides a short-range or “seed” grant (usually $25,000- $50,000 per year for 1-2 years, direct costs only) to attract new investigators to the CMD field and assist existing investigators to support early phases of their research. The short-range grant focus is to collect preliminary data and test initial hypotheses. The short-range grant goal is to translate successful preliminary research to either second tier Cure CMD midrange grants (R-21 type) or third tier, long range (R-01 grants, 2-5 years) from outside funding sources, such as the National Institutes of Health. Annual RFA deadline, Sept 15th. Grant application above. On the first page of the Cure CMD grant application, please specify Elisabeth Giauque Short Term CMD Research Grant.
info@curecmd.comCure CMDP.O. Box 701Olathe, KS 66051Ph. 1-866-400-3626
American Society for Clinical Pharmacology and Therapeutics Young Investigator Award
ASCPT is now accepting applications for the 2010 Young Investigator Award (YIA). The YIA award is intended to support a fellow or junior faculty member in clinical pharmacology or related field. The award includes a $35,000 grant. Deadline for applications is May 13, 2010.
The Young Investigator award is intended to support a fellow or junior faculty member in clinical pharmacology or related field who is engaged in clinical/translational research.
ASCPT broadly defines clinical research to be investigation in clinical pharmacology that is hypothesis-driven research that is focused on drug discovery and molecular research, drug development, drug action and disposition, clinical trials, regulatory sciences, therapeutics and outcomes research. Our focus is on human-based research.
The applicant must have completed a doctoral degree (MD, PharmD or PhD) at the time of grant award (July 2010) and be in a fellowship program focused on clinical pharmacology or must be within one year of the anniversary date of their faculty appointment.
• An application will be made by the applicant that describes the applicant, mentor, institution, and project. The ASCPT selection committee will critically evaluate these applications.• An institutional commitment for a faculty appointment at time of grant submission is not required but the applicant should be working in a laboratory or clinical research setting.• The sponsoring facility must be an academic medical institution. The primary mentor must be in the candidate’s proposed research field, must assume responsibility, and provide guidance for the research.• Applicants must provide evidence that IRB approval is pending at the time of application.• If the mentor is not an active ASCPT member, a supporting letter from an ASCPT member must beincluded.• Applicants should be planning an investigative career in clinical pharmacology.• It is expected that at the time of the award, the applicant be a member of ASCPT.• The applicant should spend at least 60-75% of his or her time in research during the award period.• Eligible candidates may submit only one application to ASCPT per year.• The Grant is for a one-year period, July 1, 2010 - June 30, 2011, for the total amount of $35,000.
Payments are made to the applicant’s institution in two equal installments on July 1 and January 1. The grantis comprised of $31,000 to support the grant project, $1,500 for travel related to the project including theASCPT Annual Meeting and $2,500 for the institution to help defray the costs related to the administration ofthe project. Disbursement of funds is contingent upon final IRB approval. If final IRB approval if not given, the award will not be granted.
• The grant funds are directed to the sponsoring institution and may provide salary support, supplies, equipment, travel, etc. necessary for pursuit of the recipient’s research project.• At the conclusion of the grant period, a final report is required highlighting the project’s progress and summarizing the usage of funds.• In accordance with the goals of the ASCPT to assist with the careers of young investigators, recipients are required to respond to ASCPT’s requests for information on their career progress following the active grant.
The Young Investigator Award information can be downloaded from the ASCPT web site at www.ascpt.org
Questions about the Young Investigator Award can be directed to:Sharon J. Swan, CAE, ASCPT Executive DirectorSharon@ascpt.org or 703.836.6981
Applications are due to ASCPT by:5:00 pm Eastern time on Thursday, May 13, 2010Applications should be sent to:ASCPT, 528 North Washington Street, Alexandria, VA 22314 USA
Request for Proposals: Novel Approaches to Drug Discovery for Alzheimer’s Disease
ADDF funds drug discovery research programs from domestic and international investigators in academia and biotechnology companies. In addition, ADDF initiates, sponsors, and co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation, bringing together physicians, scientists, and policy makers worldwide.
As a biomedical venture philanthropy, ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development. We fund high risk, early stage drug discovery and development projects and catalyze scientists to enter the drug discovery field. We have adapted the operating model and principles of venture capital investing to our philanthropic mission in biomedical research. We help to create new biotechnology companies, and to fund early stage biotechnology companies, with programs dedicated to Alzheimer’s disease drug discovery. We seek a return on investment for all of our grants based on the achievement of scientific milestones. When these milestones are met, funds return to the Foundation to increase our ability to support more research.
ADDF FUNDING PROGRAMS • ADDF Academic Drug Discovery and Development Program seeks to create and support innovative translational programs for Alzheimer’s disease, related dementias and cognitive aging in academic medical centers and universities. Biomarker development studies and innovative proof of concept pilot clinical trials of new approaches to treatment, prevention and early detection are also supported.
• ADDF Biotechnology Development Program supports qualified scientific projects in existing, private, early-stage biotechnology companies. ADDF will provide support for qualified projects in more advanced companies if a clear need for non-profit funding to support the project can be demonstrated and justified.
• ADDF Biotechnology Founders Technology Transfer Program supports academic programs that are eligible for technology transfer and the start-up of new biotechnology companies. Up to 35% of funds from these awards may be employed for expenses related to company formation, such as administrative, legal, patent and third-party vendor costs. RESEARCH FUNDING PRIORITIES • Treatment of Alzheimer’s disease and cognitive aging: ADDF supports drug discovery and drug development efforts towards novel treatments for Alzheimer’s disease and related dementias, and cognitive decline associated with aging. These may include disease modifying agents for preventing or delaying progression as well as cognitive enhancers. ADDF provides funding for target validation and proof-of-concept studies, high throughput screening of chemical libraries, lead discovery and optimization, rational medicinal chemistry, and pre-clinical drug development. ADDF also supports small proof-of principle clinical research studies. • Early detection and prevention: ADDF supports the development of biomarkers, such as advanced brain imaging technologies, CSF and blood tests for the early detection of mild cognitive impairment, Alzheimer’s disease and related dementias. ADDF also supports clinical research projects to improve early detection of cognitive impairment through population-based approaches that can impact large numbers of individuals at risk. GENERAL SUBMISSION GUIDELINES Grant applications are usually solicited by private invitation. Unsolicited proposals are also accepted, but inquiries with ADDF staff are encouraged to determine the Foundation’s interest prior to application. ADDF provides support for 1 year of research with potential for future follow-on funding. We seek successful long-term partnerships with investigators and research organizations.
APPLICATION PROCEDURE Full application guidelines and further information can be found on our website (www.alzdiscovery.org). All applicants are required to complete an electronic "Letter of Intent" (LOI) available on our website. After review of the LOI, we may invite a full application via email with a link to the electronic application form. ADDF will attempt to make a determination of interest within 90 days of receipt of the application.
ADDF accepts grant applications for the “General Request for Proposals” research award programs throughout the year (2010 deadlines for full proposals are January 7, April 1, July 1, and October 1).
If you would like to contact the Foundation, please call (212) 935-2402, or contact us by regular mail at the following address:Alzheimer’s Drug Discovery Foundation1414 Avenue of the Americas, Suite 1502New York, NY 10019
Special Programme for Research and Training in Tropical Diseases (TDR) Clinical Research & Development Fellowships
Supported by the Bill & Melinda Gates FoundationThe Special Programme for Research and Training in Tropical Diseases (TDR) invites researchers from developing countries to apply for a 12-month career development fellowship on Clinical Research & Development. Successful candidates will be seconded to selected pharmaceutical companies. The goal is to develop human resources to promote high quality clinical R&D in disease endemic countries (DEC). It is expected that qualified professionals will be able to enhance DEC product development capacity on diagnostics, drugs and vaccines against infectious diseases that disproportionately affect poor and marginalized populations.The programme will train individuals in situ with relevant partners in order to develop specialized skills not readily taught in academic centres, including inter alia R&D project management, regulatory requirements and good practices. Upon completing their fellowships, the individuals are expected to return to their home institutes and assume a leading role and become valuable resources in the global effort on R&D for neglected infectious diseases.
Programme descriptionTraining fellowshipWithin the context of the Clinical R&D team of the host pharmaceutical company, the trainee may be involved in activities related to : * Elaboration of the Clinical Development Plan; * Study preparation: study design, concept and main protocols, case report form and logistics; * Study implementation and conduct: pre-study contacts, study initiation and monitoring; * Study reporting: data validation, study report; * Medical Safety and regulation: reporting and management of safety, production of safety documents; * Administration and documentation: filing, tracking, financial agreement; * Regulatory aspects of medications; * Project planning and monitoring: human and financial resources management, timing; * Literature review, attendance at scientific meetings, clinical trial methodology, FDA/ICH requirements, new technologies.Although all companies are expected to provide the trainees with good exposure to general technical and managerial principles of R&D practices, individual programmes will be established within each company according to ongoing activities and trainee field of interest and expertise.
Alumni Network and post-training opportunitiesAn electronic alumni network will be organized and a meeting of past and current fellows will be held annually. The alumni network will contribute to the long-term sustainability of the programme by providing a forum for ongoing communication, better interaction and collaboration.
Eligibility criteriaThe applicant must: * be a scientist who is a citizen of and resident in a developing country; * be a maximum of 35 years old at the time of the submission deadline; * have a MD or PhD with clinical and research experience in infectious diseases; * be employed as a staff member of a DEC research institution, university or other recognized national institution that has an element of research relevant to TDR. The applicant must have been employed by the institution or university for a minimum of 12 months prior to the date of application; * be computer literate and fluent in English or French with a good working knowledge of English; * be able to demonstrate how the training programme will be put to use upon return to their home institute and country; * be committed to work in a developing country for a minimum of three years after the completion of the grant. Application procedureThe application should be sent in electronic format (Word or PDF only) to clinicalfellows@who.int (no application form is required). Reference letters must be scanned and attached electronically. The following information should be provided:1.Full name with the family name underlined.2.Date of birth, sex and nationality (copy of information page of passport or other identification document may be requested at a later date).3.Name, address, telephone number, fax number and e-mail address of institution where the applicant is employed. All applicants must have permanent employment.4.Telephone number for personnel contact and possible interview (if not the same as institutional telephone number above #4) must be included.5.Educational qualifications, including place of study and graduation date (transcripts and copies of qualifications are not required but may be requested later).6.A description (1 page maximum) of the applicant’s current post and of the post held immediately before.7.A description (1 page maximum) of the applicant’s current work/research interests including disease(s) interest.8.A description (1 page maximum) of how the applicant, if selected, plans to apply the acquired skills and knowledge after returning to his home country/institution.9.A list of the applicant’s publications and other abstracts or presentations.10.A letter of recommendation from two senior scientists/professors that includes their address, telephone numbers, fax numbers and e-mail addresses. Please scan and include these with the application.11.An endorsement from the Director of the applicant’s home institution testifying to the ability of the applicant to undertake successfully the training proposed and certifying that the applicant, if selected, will be granted a leave of absence. The Director should also indicate how the proposed training will strengthen the institution’s capability to conduct clinical research upon the return of the trainee.12.Applicants from countries requiring national endorsement should submit their applications through proper government channels. A copy of all applications should be sent to the WHO Representative’s Office in their home country for information purposes.All applications must be received at clinicalfellows@who.int by 6 April 2010For further information:Dr Christine Maure, Empowerment Technical officerSpecial Programme for Research and Training in Tropical DiseasesWorld Health Organization, 1211 Geneva 27, SwitzerlandTelephone: (41-22) 791-1532 Fax: (41-22) 791-4854E-mail: maurec@who.intCandidates matching the eligibility criteria will be contacted to arrange a telephone interview in May/June 2010.Applicants will be informed of the outcome in July 2010.Training will begin by mutual consent as soon as possible.Financial provision will be made available to successful applicants through TDR to cover a monthly stipend, travel, health insurance, computer, alumni membership and professional meeting participation.
Medicinal Chemistry and Drug Metabolism/Pharmacokinetics Partners to Support Lead Discovery for Infectious Tropical Diseases
TDR is supporting innovative research on neglected disease through focused and time-limited activities. The Lead Discovery Business line of TDR (LDR) aims to facilitate the discovery of new drug leads for infectious tropical diseases through North- South networks and partnerships between public and private sectors as well as academic institutions. Through the TDRs screening activities, several confirmed hits and lead compounds have become available for further SAR exploration and progression for several TDR target diseases including schistosomiasis, onchocerciasis, filariasis, African sleeping sickness, leishmaniasis, Chagas disease, malaria and tuberculosis.We are now seeking partners with expertise in medicinal chemistry, and DMPK to take on the optimization of available molecules evaluated through the TDR screening network. We strongly encourage applications from developing countries as we hope that work on these molecules will contribute to development of innovation in developing countries and contribute to the implementation of emerging regional innovation networks exemplified by the African Network for Drugs and Diagnostics Innovation (ANDI) and ongoing discussions for Asian and South American Networks.Project descriptionAcademic and research institutions, biotech and pharmaceutical companies possessing processes and capabilities in medicinal chemistry, drug metabolism and/or pharmacokinetics are encouraged to apply. Collaboration objectives are to: * Support development of molecules through different research stage (Hit to Lead and Lead optimization) * Work as part of the TDR drug discovery network and reporting of SAR data (chemical or biological information) to the TDR database * Collaborate with the existing North South screening or DMPK networks of TDR for biological testing of compounds * Participate in the development of project objectives, timelines, as well as implementation of action points identified by the TDR drug discovery committee. * Participate in the identification of downstream partners for further compound progression and development, for example, transfer of project to the regional networks including local public private partnerships. * Support training of fellows from disease endemic countries as an integral part of the project. Candidate SelectionProposals will be evaluated on the basis of the following criteria: experience and track record and experience of Principal Investigator (PI) and institution in synthetic or medicinal chemistry and DMPK, availability of basic infrastructure for synthetic/medicinal chemistry and DMPK, access to primary in vitro screens, and ability to guide post-doctoral chemists in the synthesis of analogues to explore SAR for optimization of anti-parasitic activity of compounds. Applicants are asked to develop a detailed implementation proposal covering technical and capacity building elements, budget and timelines.DeadlineThe deadline for proposals is March 31st 2010. Selected applicants will be contacted after the reviewing process.How to applyPlease contact Ms Socorro Alias with any queries. The TDR Collaborative Research Grant form template should be used for all proposals.On completion please submit electronically to aliass@who.int before the above deadline. Any additional documents may be submitted as appendices to this form (e.g. CVs of PI and research team, institutional letter of support).
TDR, a Special Programme for Research and Training in Tropical Diseases, is a global programme of scientific collaboration that helps coordinate, support and influence global efforts to combat a portfolio of major diseases of the poor and disadvantaged.Established in 1975, TDR is based at and executed by the World Health Organization (WHO), and is sponsored by the United Nations Children's Fund (UNICEF), the United Nations Development Programme (UNDP), the World Bank and WHO.
Special Programme for Research & Training in Tropical Diseases (TDR)World Health OrganizationAvenue Appia 201211 Geneva 27SWITZERLAND
National Lipid Association Abstract Award: Young Investigator: Novel Research Findings
Abstract Submission Deadline: March 15, 2010Note: The National Lipid Association is accepting a limited number of posters so get your submissions in early!Accepted abstracts will be published in the May/June 2010 issue of the NLA official journal, Journal of Clinical Lipidology.
Requirements: In-training students, residents and fellows, or members in practice for < 5 years Lead presenters who are Young Investigators (with accepted Abstracts) will receive a $300 travel voucher and free registration to the 2010 NLA Scientific Sessions. Submissions will also be eligible for the NLA Young Investigator Award. Young Investigator Award Posters submitted by young investigators will be eligible to win the NLA 2010 Young Investigator Award. Posters will be judged on scientific merit, presentation style and overall impression and the top ranked presenter will be awarded $500 and a plaque at a special ceremony on Saturday, May 15, 2010.
Submission TopicsTo ensure that your abstract receives proper consideration, be sure that the abstract relates to an appropriate topic in the field of clinical lipidology and cardiovascular disease prevention.Abstract submission topics include: * Pharmacological Control of Lipids and Lipoproteins * Epidemiology of Cardiovascular Disease * Pathophysiology of Lipids and Lipoproteins * New Therapies, Drugs in Development * HDL Modification, HDL Raising Drugs * Hypertriglyceridemia * Diabetic Dyslipidemia * Metabolic Syndrome * Obesity * Cardiometabolic Risk Reduction * Omega-3 fatty acids * Clinical Applications of Lipid and Lipoprotein Testing * Markers of Cardiovascular Risk * Lipid Management in Special Populations * Diet/Nutrition and Exercise Therapies * Lipid Clinic Management Best PracticesSubmission ProcessAbstracts for poster entries submitted for competition can only be accepted electronically and must be fewer than 400 words (including any tables or graphics) and adhere to the following guidelines: 1. Identify an abstract submission topic 2. Divide the abstract into sections: Title, Synopsis, Objectives/Purpose, Methods, Results, and Conclusion that states the importance and potential implications of the observations. 3. Use generic drug names only 4. Disclose all financial relationships for lead and secondary authors 5. Proofread your abstractAbstract Acceptance and PresentationAbstract grading is blinded and abstracts are pre-screened and selected by NLA judges on the basis of merit. You will be notified by March 19, 2010 if your poster is accepted. All lead poster presenters are expected to attend the NLA Annual Scientific Sessions in Chicago, May 13 - 16, 2010, to field questions from NLA judges and attendees. Poster guidelines will be provided to lead presenters in late March.Questions: Contact Adam Beamer at 904.309.6210
Siemens Healthcare Diagnostics Young Investigator Award
Honors outstanding laboratory research in clinical microbiology or antimicrobial agents and is intended to further the career development of a young clinical scientist and promote awareness of clinical microbiology as a career. Eligibility:The nominee should be conducting outstanding research in clinical microbiology, automation in clinical laboratories, development of novel antimicrobial agents, mechanisms of action of antimicrobial agents or mechanisms of resistance to antimicrobial agents. The nominee must be no more than five years beyond completion of postdoctoral research training in microbiology, infectious diseases or related disciplines at the time of the nomination deadline. Award:A cash prize of $2,000, commemorative piece, and travel to the ASM General Meeting.Deadline: October 1.Nominations: Nominations will be considered for three years as long as the nominee continues to meet the eligibility criteria and an updated curriculum vitae is submitted annually. Self-nominations and more than one nomination per nominee will not be accepted. Only one nominating form and two supporting forms are accepted per nomination. The two supporters must be persons other than the nominator who are familiar with the nominee's qualifications and accomplishments. Only one of the three individuals involved in the nomination may be employed at the nominee's institution. The nominator and supporters must not share employers. Nominations must consist of the following: * Curriculum vitae, including a list of publications, abstracts, and manuscripts in preparation, emailed to awards@asmusa.org * Nominating form * Supporting formASM awards are granted at the discretion of award selection committees and may not be awarded every year.Sponsor: Siemens Healthcare Diagnostics
American Society for Microbiology1752 N Street, N.W.Washington, D.C. 20036-2904(202) 737-3600
12next
